Yeda Research and Development Company Ltd.
P.O. Box 95
Rehovot
76100
Tel: 08-947-0617
Fax: 08-947-0739
Website: http://yeda.weizmann.ac.il/
Email: info.yeda@weizmann.ac.il
15 articles with Yeda Research and Development Company Ltd.
-
Biotech companies are partnering with other biotech companies to combine their cutting-edge technology platforms in hopes of opening up new avenues for drug development.
-
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders
1/25/2022
Monte Rosa Therapeutics, Inc. announced a license and research collaboration agreement with Dr. Nir London and the Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science, which aims to accelerate the discovery and development of novel covalent molecular glue degraders leveraging CoLDR.
-
CoImmune, Inc. Announces Research Collaboration with Yeda Research and Development Company Ltd.
11/17/2021
CoImmune, Inc. announced a research collaboration with Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science, to evaluate the applications of the Synthetic Immune Niche technology, developed by Weizmann Institute’s researchers to enhance the expansion and function of human cytokine induced killer cells expressing chimeric antigen receptors.
-
BioSpace Global Roundup, Jan. 9
1/9/2020
Pharma and biotech companies from across the globe provide business and pipeline updates. -
Yeda, the Commercial Arm of the Weizmann Institute of Science, and Deerfield Create Orchard Innovations, LLC
1/6/2020
Deerfield Commits up to $130 million to Advance New Medicines at the Israeli Institute Through a Newly Launched Company
-
The Stockton Group And Yeda Research and Development Company Ltd. Sign An Extension To Their Joint Research Agreement
6/6/2016
-
Stem Cell Medicine Signs License And Research Agreement With RAMOT And Yeda Research and Development Company Ltd. To Develop Stem Cell-Based Treatments For Neuronal Diseases
12/2/2015
-
TxCell Secures Key CAR-Treg Patent Through Exclusive Option Agreement With Yeda Research and Development Company Ltd., The Commercial Arm Of World's Recognized Weizmann Institute of Science
11/2/2015
-
XTL Biopharmaceuticals Ltd. Announces Agreement With Yeda Research and Development Company Ltd. To Amend License Agreement For Lupus Asset
10/13/2015
-
Hyperion Therapeutics Enters Into Completion Of Phase III Clinical Trial, Option And Mutual Release Agreement With Clal Biotechnology Industries And Yeda Research and Development Company Ltd.
2/17/2015
-
PROLOR Biotech Signs Exclusive License Agreement With Yeda Research and Development Company Ltd. for Long-Acting Peptides and Small Molecules Including Oxyntomodulin for Anti-Obesity Applications
1/18/2011
-
PROLOR Biotech Acquires License Option from Yeda Research and Development Company Ltd. for Development of Long-Acting Anti-Obesity Drug
7/27/2009
-
The Day In Review: Connetics Corporation Wins FDA Approval Of Verdeso Foam
9/20/2006
-
Amgen Announces License Agreement With Yeda Research and Development Company Ltd.
9/20/2006
-
ImClone Systems Incorporated Issues Statement On Court Ruling In Litigation Against Yeda Research and Development Company Ltd.
9/19/2006